BridgeBio Pharma, Inc, trading under the symbol BBIO, is a biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for genetic diseases. Founded in 2015, the company is based in Palo Alto, California, and operates worldwide.
With the genetic diseases being the company's core focus, BridgeBio mainly targets specific mutations in a patient that can cause or significantly contribute to a particular disease. They strive to create therapies by identifying the genetically-driven conditions' right target and develop the best possible delivery methodology.
BridgeBio’s approach is patient-oriented — listening to patients, their families, and their physicians, studying the disease's natural history, and comprehending the genetic science that leads to disease manifestations. The combination of scientific, clinical, and commercial expertise helps the company understand, confront, and potentially change the course of terrible diseases.
To translate scientific discoveries to the clinic rapidly, BridgeBio has built a unique portfolio of product candidates which include more than 30 development programs ranging from early discovery to late-stage development. Notably, the company's therapies in dermatology, cardiology, neurology, endocrinology, renal disease, and ophthalmology are substantially advancing in clinical trials.
The company follows a novel business model where each product candidate is developed by a separate subsidiary. This innovative model aids in focusing the energy and expertise on each separate program while keeping resource allocation efficient and execution-focused.
BridgeBio's mission is written in its name: it serves as a bridge from the discovery of genetic diseases to a future where the diseases are treatable. Their ultimate goal being, transforming the lives of patients who currently have little to no therapeutic options.
The journey to bring impactful medicines to patients is a long and challenging one. But with an excellent leadership team, comprising biotech industry veterans and successful entrepreneurs, and the dedication to scientific innovation, BridgeBio is committed to the advancement of genetic medicines. By pursuing a wide variety of genetic diseases with substantial unmet medical needs and by tirelessly working to develop pioneering treatments, BridgeBio Pharma is making a significant impact in the pharmaceutical industry as well as in the lives of those who need it most.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
BridgeBio Pharma (BBIO) announced that its drug acoramidis showed a 34% lower risk of early clinical worsening and better results for early heart failure progression markers compared to tafamidis in a new peer-reviewed real-world study for ATTR-CM. The study also noted a 43% lower risk of diuretic intensification with acoramidis. This data supports the narrative of acoramidis as a key growth driver for BridgeBio Pharma, reinforcing its differentiation in the treatment of ATTR-CM.
BridgeBio Pharma announced that its heart disease therapy, acoramidis (Attruby), demonstrated superior performance compared to Pfizer's tafamidis (Vyndamax) in a real-world study. Attruby received FDA approval in November 2024 for transthyretin cardiac amyloidosis. This news highlights a potential competitive advantage for BridgeBio in the cardiovascular treatment market.
BridgeBio Pharma (BBIO) stock has experienced a significant 12.4% drop over seven consecutive trading days, resulting in a $1.9 billion reduction in its market value. Despite rapid revenue growth of 202.4% over the last twelve months, the company faces substantial operating losses with a margin of -67.0%. The article emphasizes that while such a streak highlights downward momentum, investors should focus on fundamentals rather than reacting solely to price movements.
BridgeBio Pharma (BBIO) shares have dropped 10.7% since its last earnings report, underperforming the S&P 500. The company reported a wider-than-expected Q2 2026 loss per share but revenues surged, primarily driven by strong sales of Attruby. Analyst estimates have shown a downward trend for the stock, which currently holds a Zacks Rank #3 (Hold).
BridgeBio Pharma (BBIO) stock has experienced an 8.8% decline over nine consecutive trading days, resulting in a $1.4 billion market value loss. Despite this recent slide, the stock has shown significant returns over the trailing three and twelve months, and its revenue growth is substantial. The article highlights that the decline is specific to the company and suggests re-evaluating the business fundamentals rather than reacting solely to the momentum.
President Donald Trump announced new drug pricing deals with the U.S. affiliate of Teva Pharmaceutical Industries and eight other midsize companies. This builds on previous agreements, bringing the total number of major pharmaceutical companies with pricing agreements with the Trump administration to 17. The announcement was made during an event in the Oval Office.